New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
13:25 EDTJAZZ, JAZZ, JAZZ, SLXP, SLXP, SLXPLeerink's specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gerberry discusses the prospects for Jazz Pharmaceuticals/Sigma Tau's Defibrotide approval in the U.S., and provides an assessment of challneges facing two key specialty pharma controversies: Defibrotide and Relistor on an Analyst/Industry conference call to be held on February 27 at 2 pm.
News For JAZZ;SLXP From The Last 14 Days
Check below for free stories on JAZZ;SLXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:51 EDTJAZZOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 15, 2014
17:32 EDTSLXPSalix announces tentative FDA approval of UCERIS rectal foam
Subscribe for More Information
15:55 EDTSLXPSalix price target raised to $172 from $163 at Buckingham
Subscribe for More Information
15:41 EDTSLXPSalix calls active on takeover chatter
Subscribe for More Information
07:47 EDTSLXPFDA PDUFA Date for Salix Pharmaceuticals Budesonide is September 15, 2014
September 12, 2014
10:00 EDTSLXPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:06 EDTSLXPFollow-up: Salix initiated with an Underperform at Credit Suisse
Subscribe for More Information
06:41 EDTSLXPSalix initiated with an Underperform at Credit Suisse
Subscribe for More Information
September 8, 2014
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:21 EDTSLXP, JAZZJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 5, 2014
11:40 EDTJAZZJazz Pharmaceuticals calls active on renewed takeover speculation
Subscribe for More Information
11:00 EDTJAZZRumor: Jazz Pharmaceuticals strength attributed to renewed takeover speculation
Subscribe for More Information
September 3, 2014
07:47 EDTJAZZJazz Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information
September 2, 2014
07:21 EDTSLXPSalix submits response to FDA's CRL regarding XIFAXAN 550 mg tablets sNDA
Salix Pharmaceuticals announced that on August 29, it submitted its response to the March 7, 2011, FDA Complete Response Letter, or CRL, regarding the Company’s supplemental New Drug Application, or sNDA, for XIFAXAN 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix’s response, the FDA will have six months to issue a response.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use